Deal Ticker: Kellerhals Carrard acted as lead counsel in connection with Biognosys’ strategic partnership with Bruker Corporation

Biognosys AG and Bruker Corporation (Nasdaq: BRKR) announced a strategic partnership, in which Bruker has made a majority-ownership investment in Biognosys. Financial details were not disclosed. Several of Biognosys’ earlier investors have sold their shares to Bruker in a secondary transaction, and Bruker will make new primary investments in Biognosys.

Kellerhals Carrard advised Biognosys AG and the majority of its shareholders on this transaction. The team was comprised of Karim Maizar (M&A/VC), Nicolas Mosimann (M&A/VC), Michèle Remund (Tax) as well as Dario Silberschmidt (M&A/VC), Vanessa Witschi (M&A/Tax) and Sarah Schneider (M&A/VC).

Biognosys mass spectrometry-based proteomics solutions help CRO services and proteomics software customers in uncovering connections between genome, transcriptome, and phenotype to explore the static and dynamic nature of disease biology. The Bruker-Biognosys collaboration is expected to create unique synergies between Biognosys’ versatile portfolio of proprietary proteomics services, software and kits, and Bruker’s pioneering timsTOF platform. As a result of the strategic partnership, Biognosys plans to open its first advanced proteomics CRO services laboratory in the United States.